By Erin Marie Daly ( February 8, 2008, 12:00 AM EST) -- Still smarting from recent public scrutiny from a consumer advocacy group over Botox, Allergan Inc. has been hit with more bad news. The U.S. Food and Drug Administration announced Friday it will conduct a safety review of the popular cosmetic treatment and a similar product, Myobloc, after receiving reports of deaths and breathing problems in some patients....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.